Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients

References

• Hosking D, Adami S, Felsenberg D, Andia J C. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized, placebo-controlled study. Curr Med Res Opin 2003; 19: 383–394
   PubMed Web of Science ®Google Scholar
• Susan L, Greenspan S L, Rosen H N, Parker R A. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000; 85: 3537–3540
   PubMed Web of Science ®Google Scholar
• Tonino R P, Meunier P J, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000; 85: 3109–3115
   PubMed Web of Science ®Google Scholar
• Greenspan S L, Parker R A, Ferguson L, Rosen H N, Maitland-Ramsey L, Karpf D B. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998; 13: 1431–1438
   PubMed Web of Science ®Google Scholar
• Fogelman I, Ribot C, Smith R, Ethgen D. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85: 1895–1900
   PubMed Web of Science ®Google Scholar
• Harris S T, Watts N B, Genant H K, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344–1352
   PubMed Web of Science ®Google Scholar
• Allen M R, Iwata K, Sato M, Burr D B. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 2006; 39: 1130–1135
   PubMed Web of Science ®Google Scholar
• Hochberg M C, Ross P D, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999; 42: 1246–1254
   PubMed Web of Science ®Google Scholar
• Chesnut C H, Bell N H, Clark G S, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 102: 29–37
   PubMed Web of Science ®Google Scholar
• Estell R, Barton I, Hannon R. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051–1056
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Duboeuf F. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: OFELY Study. J Bone Miner Res 1999; 14: 1614–1621
   PubMed Web of Science ®Google Scholar
• Delmas P D, Eastell R, Garnero P, Seibel M J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000; 6: s2–17
   Google Scholar
• Garnero P, Shih W J, Gineyts E, Karpf D B, Delmas P D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–1700
   PubMed Web of Science ®Google Scholar
• Briot K, Tremollieres F, Thomas T, Roux C. How long should patients take medications for postmenopausal osteoporosis?. Joint Bone Spine 2007; 74: 24–31
   PubMed Web of Science ®Google Scholar
• Benhamou C L. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007; 74: 39–47
   PubMed Web of Science ®Google Scholar
• Miller P D. Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis. Expert Opin Pharmacother 2003; 4: 2253–2258
   PubMed Web of Science ®Google Scholar
• Reginster J Y. Adherence and persistence: impact on outcomes and health care resources. Bone 2006; 38: S18–21
   PubMed Web of Science ®Google Scholar
• Reid D M. Once-monthly dosing: an effective step forward. Bone 2006; 38: S18–22
   PubMed Web of Science ®Google Scholar
• Reginster J Y, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006; 38: S2–6
   PubMed Web of Science ®Google Scholar
• Odvina C V, Zerwekh J E, Rao S, Maalouf N, Gottschalk F A, Pak C Y. Severe suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endorinol Metab 2005; 90: 1294–1301
   PubMed Web of Science ®Google Scholar
• Karsdal M A, Qvist P, Chritiansen C, Tanko L. Optimising antiresorptive therapies in postmenopausal women. Drugs 2006; 66: 1909–1918
   PubMed Web of Science ®Google Scholar
• Garnero P, Darte C, Delmas P D. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 1999; 24: 603–609
   PubMed Web of Science ®Google Scholar
• Alvarez L, Peris P, Guanabens N, et al. Long-term biochemical response after bisphosphonates therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Rheumatology 2004; 43: 869–874
   PubMed Web of Science ®Google Scholar
• Delmas P D, Hardy P, Garnero P, Dain M P. Monitoring individual response to hormone replacement therapy with bone markers. Bone 2000; 26: 553–560
   PubMed Web of Science ®Google Scholar
• Cao Yongping, Mori S, Mashiba T, Westmore M S. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002; 17: 2237–2246
   PubMed Web of Science ®Google Scholar
• Silverman S L, Watts P D, Delmas P D, Lange J L, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study. Osteoporosis Int 2007; 18: 25–34
   PubMed Web of Science ®Google Scholar